News & Updates

Show Multimedia Only

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

26 Jan 2026

Patients with hepatocellular carcinoma (HCC) weighing <55 kg who initiate a full dose of lenvatinib tend to lose weight or discontinue treatment, reports a study.

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

26 Jan 2026

Berberine of little benefit in individuals with obesity and MASLD

26 Jan 2026

Treatment with berberine in diabetes-free individuals with obesity and metabolic dysfunction–associated steatotic liver disease (MASLD) is safe but falls short of reducing visceral adipose tissue (VAT) and liver fat content, as reported in a study.

Berberine of little benefit in individuals with obesity and MASLD

26 Jan 2026

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026 by

The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026

Mediterranean, plant-based diets vital in MASLD management

12 Jan 2026 by

Dietary interventions continue to provide benefits in the management of chronic liver diseases and serve as a valuable addition to pharmacotherapy options available, reports a study.

Mediterranean, plant-based diets vital in MASLD management

12 Jan 2026

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026 by

A recent study has demonstrated the long-term safety of mirikizumab in patients with moderate to severe active ulcerative colitis (UC), with no new significant safety concerns.

Long-term use of mirikizumab does not raise new safety signals

11 Jan 2026

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

In addition to improving glycaemic control, the use of SGLT2 inhibitors also appears to reduce mortality, hospitalization, cardiovascular events, and liver complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

09 Jan 2026

Which social determinant predicts MASLD prevalence, severity?

08 Jan 2026

Among several social determinants of health (SDOHs), diet quality is most consistently associated with disease prevalence and severity in metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Which social determinant predicts MASLD prevalence, severity?

08 Jan 2026

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

18 Dec 2025 by

The LIVE-SMART trial presented at AASLD 2025 shows that lactulose and Tai chi may prevent falls in individuals with cirrhosis and portal hypertension.

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

18 Dec 2025

Tinengotinib shows promising activity against cholangiocarcinoma

16 Dec 2025

In patients with cholangiocarcinoma with FGFR2 fusions that progressed following FGFR inhibitor therapy, tinengotinib has demonstrated potential antitumour activity in a phase II study.

Tinengotinib shows promising activity against cholangiocarcinoma

16 Dec 2025

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

15 Dec 2025 by

The post hoc subgroup analysis of the phase III MITIGATE trial shows the benefit of the humanized monoclonal anti-CD19 antibody inebilizumab in adults with IgG4-related disease (IgG4-RD) with pancreas, bile duct, and liver involvement at baseline.

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

15 Dec 2025

News & Updates

Showing Hepatology articles

Showing

Specialty:

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

Body weight predicts dose reduction, discontinuation in HCC patients taking lenvatinib

Berberine of little benefit in individuals with obesity and MASLD

Berberine of little benefit in individuals with obesity and MASLD

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Mediterranean, plant-based diets vital in MASLD management

Mediterranean, plant-based diets vital in MASLD management

Long-term use of mirikizumab does not raise new safety signals

Long-term use of mirikizumab does not raise new safety signals

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

SGLT2 inhibitors improve cardiovascular, hepatic outcomes in MASLD patients

Which social determinant predicts MASLD prevalence, severity?

Which social determinant predicts MASLD prevalence, severity?

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

Lactulose, Tai chi prevent falls in patients with cirrhosis, portal hypertension

Tinengotinib shows promising activity against cholangiocarcinoma

Tinengotinib shows promising activity against cholangiocarcinoma

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement

Inebilizumab MITIGATEs flares in IgG4-RD with pancreatic, hepatobiliary involvement